A carregar...
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angioge...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165211/ https://ncbi.nlm.nih.gov/pubmed/34079777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S251729 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|